Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Payables: 2010-2025

Historic Payables for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $4.5 million.

  • Lineage Cell Therapeutics' Payables rose 1.63% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 9.47%. This contributed to the annual value of $5.4 million for FY2024, which is 13.29% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Payables stood at $4.5 million for Q3 2025, which was up 2.22% from $4.5 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Payables high stood at $28.0 million for Q4 2021, and its period low was $4.5 million during Q2 2025.
  • Over the past 3 years, Lineage Cell Therapeutics' median Payables value was $5.0 million (recorded in 2024), while the average stood at $5.1 million.
  • In the last 5 years, Lineage Cell Therapeutics' Payables soared by 310.52% in 2021 and then crashed by 69.22% in 2022.
  • Lineage Cell Therapeutics' Payables (Quarterly) stood at $28.0 million in 2021, then crashed by 69.22% to $8.6 million in 2022, then declined by 27.16% to $6.3 million in 2023, then dropped by 13.29% to $5.4 million in 2024, then climbed by 1.63% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4.5 million for Q2 2025, and $5.0 million during Q1 2025.